Drug intelligence / Profile preview

GS-5737

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Inhalation

Overview

GS-5737 is an inhaled small molecule inhibitor of the epithelial sodium channel (ENaC) developed by Gilead Sciences. It is being investigated for its potential to enhance mucociliary clearance (MCC) in patients with obstructive lung diseases, including cystic fibrosis and chronic obstructive pulmonary disease (COPD). By blocking ENaC-mediated sodium reabsorption in the airway epithelium, GS-5737 helps maintain airway surface liquid hydration, which is critical for effective mucus transport and lung defense. The drug is typically formulated in hypertonic saline to further support mucus hydration and clearance.

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on GS-5737.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-5737.

Explore the full profile